Optimata, Developer of Virtual Patient Biosimulation Technologies, Appoints Dr. David Sidransky to Scientific Board.RAMAT GAN, Israel -- Optimata Ltd., the developer of Virtual Patient biosimulation technologies, today announced the appointment of Dr. David Sidransky to the company's scientific board. Dr. Sidransky is a world-renowned cancer researcher and a consultant to a number of leading biotechnology companies. He was named by Time Magazine and CNN CNN or Cable News Network Subsidiary company of Turner Broadcasting Systems. It was created by Ted Turner in 1980 to present 24-hour live news broadcasts, using satellites to transmit reports from news bureaus around the world. as one of America's top 18 scientists and doctors. "We are tremendously excited to have an individual of Dr. Sidransky's stature as part of our team. We believe that his cutting-edge expertise in the study of cancer and biomarkers will strongly benefit our R&D program," said Prof. Zvia Agur, Chairperson and Chief Scientific Officer. "Dr. Sidransky has already collaborated with us and closely observed in action Optimata's Virtual Patient technologies for the biosimulation of drug development and therapy. We look forward to his ongoing participation as we move ahead with our parallel tracks of market entry and technology validation studies," said Guy Malchi, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Optimata. David Sidransky, M.D. is the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine The Johns Hopkins University School of Medicine, located in Baltimore, Maryland, USA, is a highly regarded medical school and biomedical research institute in the United States. . In addition, he is Professor of Oncology, Otolaryngology-Head and Neck Surgery, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at John Hopkins University and Hospital.. He has served as a director of Imclone since January 2004. He is a founder of several private biotechnology companies and has served on numerous scientific advisory boards of many private and public companies, including Medimmune, Telik, Roche and Amgen. Dr. Sidransky is also a director of Alfacell Inc. He was formerly on the board of scientific counselors at the NIDCR NIDCR National Institute of Dental and Craniofacial Research. and a member of the Recombinant DNA recombinant DNA n. Genetically engineered DNA prepared by transplanting or splicing one or more segments of DNA into the chromosomes of an organism from a different species. Such DNA becomes part of the host's genetic makeup and is replicated. advisory committee at the National Institute of Health NIH "Not invented here." See digispeak. NIH - The United States National Institutes of Health. (RAC See remote access concentrator. ). Dr. Sidransky is on numerous editorial boards and is senior editor of Clinical Cancer Research. He is a board member of the American Association of Cancer Research (AACR AACR American Association for Cancer Research AACR Anglo-American Cataloging Rules AACR Australasian Association of Cancer Registries AACR African Armed Conflicts Resolved ). Dr. Sidransky is certified in Internal Medicine and Medical Oncology by the American Board of Medicine. He has over 250 peer-reviewed publications, and has contributed more than 40 cancer reviews and chapters and also has numerous issued biotechnology patents. He has been the recipient of many awards and honors, including the 1997 Sarstedt International prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians The American College of Chest Physicians (ACCP) is a medical organization consisting of physicians and non-physician specialists in the field of chest medicine, which includes pulmonology, thoracic surgery, and critical care medicine. and the 2004 Hinda and Richard Rosenthal Award from the AACR. About Optimata Optimata Ltd. is a science-based, interdisciplinary company, dedicated to the development of predictive biosimulation technologies - Virtual Patient Engines. Founded by Prof. Zvia Agur, a world-renowned biomathematician who has pioneered methods of using computer modeling for optimizing treatment protocols in cancer and pathogenic diseases, .Optimata offers a rational approach for the selection of patient populations and the optimization of drug scheduling and dosage. Optimata's technology is based on a computer-generated method of accurately predicting how individual patients or patient populations will respond to a compound. The technology combines computer models of human physiology, specific diseases and the therapeutic impact of a compound. The in-silico technology enables drug developers to conduct experiments at an unprecedented scale, enabling an unlimited number of "virtual trials" to be carried out on an almost infinite combination of dosages, treatment schedules and patient population characteristics. Major pharmaceutical company clients include Eli Lilly. The company is currently completing a bio-simulation clinical trial on individualized in·di·vid·u·al·ize tr.v. in·di·vid·u·al·ized, in·di·vid·u·al·iz·ing, in·di·vid·u·al·iz·es 1. To give individuality to. 2. To consider or treat individually; particularize. 3. breast cancer therapy in collaboration with Nottingham City Hospital Nottingham City Hospital is a large hospital located in Nottingham, UK. With Queen's Medical Centre, it forms the Nottingham University Hospitals NHS Trust. The City Hospital is the oldest of Nottingham's two hospitals, founded in 1903. in the UK and Soroka University Medical Center in Israel. For more information about Optimata visit www.optimata.com Or contact: Guy Malchi, CEO Optimata Ltd. 7 Abba Hillel Silver Street Ramat-Gan 52522 Israel info@optimata.com Tel: +972-3-7519226 Fax: +972-3-7519229 |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion